Lucas Reis Felício
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Reis Felício has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Mariano Ruas
Universidade Federal de Minas Gerais
3 shared publications - Sarah Nascimento Silva
Fundação Oswaldo Cruz
3 shared publications - Augusto Afonso Guerra Junior
Department of Social Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
1 shared publication - Bárbara Rodrigues Alvernaz dos Santos
Universidade Federal de Minas Gerais, Brazil
1 shared publication - Francisco de Assis Acurcio
Universidade Federal de Minas Gerais, Brazil
1 shared publication - Juliana Alvares-Teodoro
Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (9)
Acceso a antipsicóticos en Brasil: uso de la gestión de riesgos para evaluar cambios en los servicios farmacéuticos
Resumen El tratamiento de la esquizofrenia es esencial para la calidad de vida de los pacientes y depende del uso continuo de antipsicóticos proporcionados por el Sistema Único de Salud (SUS) de Brasil. Este estudio comparó los procesos que afectan el acceso a antipsicóticos en los componentes básicos y especializados de los servicios farmacéuticos (SF), utilizando la gestión de riesgos. La metodología identificó 20 eventos de riesgo en el ciclo de los SF, clasificándolos en niveles de muy bajo a muy alto, según la probabilidad e impacto. Ambos componentes presentan riesgos altos y muy altos: 12 en el componente básico (60%), 11 en el especializado (55%) y 7 compartidos. La comparación evidencia la necesidad de mitigación en ambos y oportunidades de mejora. Así, el mantenimiento o la transición de antipsicóticos debe considerar la capacidad de mitigar riesgos y otros criterios del contexto local. La gestión de riesgos demostró ser útil para evaluar el acceso a medicamentos y orientar decisiones en los SF.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (9)
Open AccessAcceso a antipsicóticos en Brasil: uso de la gestión de riesgos para evaluar cambios en los servicios farmacéuticos
Resumen El tratamiento de la esquizofrenia es esencial para la calidad de vida de los pacientes y depende del uso continuo de antipsicóticos proporcionados por el Sistema Único de Salud (SUS) de Brasil. Este estudio comparó los procesos que afectan el acceso a antipsicóticos en los componentes básicos y especializados de los servicios farmacéuticos (SF), utilizando la gestión de riesgos. La metodología identificó 20 eventos de riesgo en el ciclo de los SF, clasificándolos en niveles de muy bajo a muy alto, según la probabilidad e impacto. Ambos componentes presentan riesgos altos y muy altos: 12 en el componente básico (60%), 11 en el especializado (55%) y 7 compartidos. La comparación evidencia la necesidad de mitigación en ambos y oportunidades de mejora. Así, el mantenimiento o la transición de antipsicóticos debe considerar la capacidad de mitigar riesgos y otros criterios del contexto local. La gestión de riesgos demostró ser útil para evaluar el acceso a medicamentos y orientar decisiones en los SF.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (9)
Access to antipsychotic in Brazil: using risk management to assess changes in pharmaceutical services
The treatment of schizophrenia is essential for patients’ quality of life and relies on the continuous use of antipsychotics provided by the Brazilian Unified Health System (SUS). This study aimed to compare the processes that affect access to antipsychotics across different components of pharmaceutical services (PS) using risk management. The risk management methodology applied establishes risk levels, from very low to very high, based on the combination of probability and impact scales, following consecutive stages from context understanding to risk treatment. A total of 20 risk events were identified within the stages of the PS cycle. Both components show high and very high risks that need to be mitigated, with 12 in the basic component (60%), 11 in the specialized component (55%), and seven shared between the two. The component comparison indicates that both require risk mitigation and have opportunities for improvement; thus, the maintenance or transition of antipsychotics between components should be guided by the capacity to mitigate PS management risks, along with other local context criteria. Risk management proved useful in discussing medication access and guiding decision-making in PS management.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (9)
Open AccessAccess to antipsychotic in Brazil: using risk management to assess changes in pharmaceutical services
The treatment of schizophrenia is essential for patients’ quality of life and relies on the continuous use of antipsychotics provided by the Brazilian Unified Health System (SUS). This study aimed to compare the processes that affect access to antipsychotics across different components of pharmaceutical services (PS) using risk management. The risk management methodology applied establishes risk levels, from very low to very high, based on the combination of probability and impact scales, following consecutive stages from context understanding to risk treatment. A total of 20 risk events were identified within the stages of the PS cycle. Both components show high and very high risks that need to be mitigated, with 12 in the basic component (60%), 11 in the specialized component (55%), and seven shared between the two. The component comparison indicates that both require risk mitigation and have opportunities for improvement; thus, the maintenance or transition of antipsychotics between components should be guided by the capacity to mitigate PS management risks, along with other local context criteria. Risk management proved useful in discussing medication access and guiding decision-making in PS management.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (9)
Acesso aos antipsicóticos no Brasil: usando a gestão de riscos para dimensionar mudanças na assistência farmacêutica
Resumo O tratamento da esquizofrenia é fundamental para a qualidade de vida dos pacientes e depende do uso contínuo de antipsicóticos, disponibilizados no Sistema Único de Saúde (SUS). O objetivo deste estudo foi comparar os processos que interferem no acesso aos antipsicóticos nos diferentes componentes da assistência farmacêutica (AF) usando a gestão de riscos. Foi utilizada a metodologia de gestão de risco que estabelece níveis de risco, muito baixo até muito alto, a partir da combinação das escalas de probabilidade e de impacto seguindo as etapas consecutivas de entendimento do contexto, até o tratamento dos riscos. Foram identificados 20 eventos de risco envolvendo as etapas ciclo da AF. Os componentes analisados apresentam riscos altos e muito altos que necessitam ser mitigados, 12 no componente básico (60%), 11 no especializado (55%) e sete compartilhados pelos dois componentes. A comparação dos componentes aponta que ambos precisam mitigar riscos e têm oportunidades de melhorias, logo a manutenção ou a transição dos antipsicóticos entre componentes deve ser pautada na capacidade de mitigar os riscos da gestão da AF somado a outros critérios do contexto local. A gestão de riscos se mostrou útil para discutir acesso aos medicamentos e orientar a tomada de decisão na gestão da AF.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (9)
Open AccessAcesso aos antipsicóticos no Brasil: usando a gestão de riscos para dimensionar mudanças na assistência farmacêutica
Resumo O tratamento da esquizofrenia é fundamental para a qualidade de vida dos pacientes e depende do uso contínuo de antipsicóticos, disponibilizados no Sistema Único de Saúde (SUS). O objetivo deste estudo foi comparar os processos que interferem no acesso aos antipsicóticos nos diferentes componentes da assistência farmacêutica (AF) usando a gestão de riscos. Foi utilizada a metodologia de gestão de risco que estabelece níveis de risco, muito baixo até muito alto, a partir da combinação das escalas de probabilidade e de impacto seguindo as etapas consecutivas de entendimento do contexto, até o tratamento dos riscos. Foram identificados 20 eventos de risco envolvendo as etapas ciclo da AF. Os componentes analisados apresentam riscos altos e muito altos que necessitam ser mitigados, 12 no componente básico (60%), 11 no especializado (55%) e sete compartilhados pelos dois componentes. A comparação dos componentes aponta que ambos precisam mitigar riscos e têm oportunidades de melhorias, logo a manutenção ou a transição dos antipsicóticos entre componentes deve ser pautada na capacidade de mitigar os riscos da gestão da AF somado a outros critérios do contexto local. A gestão de riscos se mostrou útil para discutir acesso aos medicamentos e orientar a tomada de decisão na gestão da AF.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 19 (suppl 1)
Genetic markers involved in neuroinflammation in Down syndrome: a systematic review
The immune system plays a fundamental role in protecting human body organs and tissues; however, when exacerbated, it can contribute to the pathology of various conditions. In the central nervous system, immune cell activation, or neuroinflammation, is a key factor in several neurodegenerative diseases. In Down syndrome (DS), the additional copy of chromosome 21 alters gene expression, potentially enhancing inflammatory processes such as neuroinflammation. Therefore, understanding the genetic factors influencing neuroinflammation in DS is essential for identifying biomarkers and therapeutic targets. Objective Identify genetic markers involved in neuroinflammatory processes in individuals with DS. Methods A comprehensive search was conducted in Medical Literature Analysis and Retrieval System Online (Medline) (United States National Library of Medicine [PubMed]), Embase, Cochrane Library, and Latin American and Caribbean Health Sciences Literature (LILACS) databases, and identified ten relevant studies. These studies assessed and compared gene expression between groups with and without DS associated with neuroinflammation. Results Sixty–three genes and 42 genetic markers associated with neuroinflammation in DS were identified. These genes exhibited expression variations that alter inflammatory responses, suggesting a possible link to the progression of neurodegenerative diseases in this population. Conclusions The findings highlight the role of neuroinflammation in neurodegenerative disorders in individuals with DS, especially Alzheimer’s disease. Some studies indicated that the triplicated genes SOD1, APP, S100B, TREM2, IFNR1, and IFNR2 are directly related to neuroinflammation. Additionally, elevated levels of pro-inflammatory cytokines, such as IL–1, IL–6, IL–10, IFNγ, and TNF-α, and complement proteins like C1q, C3, and C9 suggest an exacerbated activation of the immune response. However, the roles these genes may play in neurodegenerative diseases and in increasing or reducing neuroinflammation remain controversial.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 19 (suppl 1)
Open AccessGenetic markers involved in neuroinflammation in Down syndrome: a systematic review
The immune system plays a fundamental role in protecting human body organs and tissues; however, when exacerbated, it can contribute to the pathology of various conditions. In the central nervous system, immune cell activation, or neuroinflammation, is a key factor in several neurodegenerative diseases. In Down syndrome (DS), the additional copy of chromosome 21 alters gene expression, potentially enhancing inflammatory processes such as neuroinflammation. Therefore, understanding the genetic factors influencing neuroinflammation in DS is essential for identifying biomarkers and therapeutic targets. Objective Identify genetic markers involved in neuroinflammatory processes in individuals with DS. Methods A comprehensive search was conducted in Medical Literature Analysis and Retrieval System Online (Medline) (United States National Library of Medicine [PubMed]), Embase, Cochrane Library, and Latin American and Caribbean Health Sciences Literature (LILACS) databases, and identified ten relevant studies. These studies assessed and compared gene expression between groups with and without DS associated with neuroinflammation. Results Sixty–three genes and 42 genetic markers associated with neuroinflammation in DS were identified. These genes exhibited expression variations that alter inflammatory responses, suggesting a possible link to the progression of neurodegenerative diseases in this population. Conclusions The findings highlight the role of neuroinflammation in neurodegenerative disorders in individuals with DS, especially Alzheimer’s disease. Some studies indicated that the triplicated genes SOD1, APP, S100B, TREM2, IFNR1, and IFNR2 are directly related to neuroinflammation. Additionally, elevated levels of pro-inflammatory cytokines, such as IL–1, IL–6, IL–10, IFNγ, and TNF-α, and complement proteins like C1q, C3, and C9 suggest an exacerbated activation of the immune response. However, the roles these genes may play in neurodegenerative diseases and in increasing or reducing neuroinflammation remain controversial.